Denosumab in postmenopausal women with low bone mineral density - Test2 - elhamkhani - TriplyDB

Denosumab in postmenopausal women with low bone mineral density

Denosumab in postmenopausal women with low bone mineral density

http://www.wikidata.org/entity/Q28298728

about

Role of RANKL inhibition in osteoporosis Pathophysiology of age-related diseases Denosumab for the treatment and prevention of postmenopausal osteoporosis The role of RANK-ligand inhibition in cancer: the story of denosumab Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate Roles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular Disease Bone Tumor Environment as a Potential Therapeutic Target in Ewing Sarcoma Prevention and treatment of bone fragility in cancer patient Update on denosumab in the management of postmenopausal osteoporosis: patient preference and adherence The role of "bone immunological niche" for a new pathogenetic paradigm of osteoporosis Anti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidences Screening, diagnosis and treatment of osteoporosis: a brief review A review of denosumab for the treatment of osteoporosis Biochemical markers of ongoing joint damage in rheumatoid arthritis--current and future applications, limitations and opportunities.Increasing options for the treatment of osteoporosis Key roles of the OPG-RANK-RANKL system in bone oncology RANKL/RANK-beyond bones Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients Development and evaluation of an algorithm to identify users of Prolia(®) during the early postmarketing period using health insurance claims data.Assessment of off-label use of denosumab 60 mg injection during the early postmarketing period using health insurance claims data.Therapeutic effects of radix dipsaci, pyrola herb, and Cynomorium songaricum on bone metabolism of ovariectomized rats.Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases.Ubiquitin-mediated signalling and Paget's disease of bone.Observations following discontinuation of long-term denosumab therapy.Can denosumab be a substitute, competitor, or complement to bisphosphonates?Comparative Resistance to Teriparatide-Induced Bone Resorption With Denosumab or Alendronate.Future of bisphosphonates and denosumab for men with advanced prostate cancer.Effects of Denosumab on Bone Metabolic Markers and Bone Mineral Density in Patients Treated with Glucocorticoids Antiresorptive drugs beyond bisphosphonates and selective oestrogen receptor modulators for the management of postmenopausal osteoporosis Nf1 Haploinsufficiency Alters Myeloid Lineage Commitment and Function, Leading to Deranged Skeletal Homeostasis.Pharmacological management of osteogenesis.Vitamin D and Calcium Are Required during Denosumab Treatment in Osteoporosis with Rheumatoid Arthritis.Bone health in the prostate cancer patient receiving androgen deprivation therapy: a review of present and future management options.Synergistic IL-6 and IL-8 paracrine signalling pathway infers a strategy to inhibit tumour cell migration.Interpretation of 41Ca data using compartmental modeling in post-menopausal women Osteonecrosis of the jaw in a patient on Denosumab.Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer.Bone health and prostate cancer.Bone damage in rheumatoid arthritis: mechanistic insights and approaches to prevention

P2860

Q21195417-6489432E-2E87-427A-BC52-95A2EBD48485 Q21245033-026D8A7B-46C4-4CE1-92C2-E61236ED2736 Q24201859-C0514B35-8E78-4812-8804-779E4142C59C Q24633284-2D13C0CC-8E00-4D20-B053-6DE138BEE953 Q24658507-3A613C21-C23F-4B1C-9E6C-198CB74D68B6 Q26747224-FA49521F-7F4D-4D18-B84E-99B432AD9DF3 Q26771376-BDD7FA6B-8F6E-46A6-8FC2-41AE4BF640A7 Q26775765-0F220FF6-7A2D-4B60-9B70-15B230EDEC2E Q26778291-44DBFBAC-5217-44DE-A60E-B4EE4FB3ACB6 Q26780523-3DF3A3A3-944B-4B75-A0D7-EEBF165C7474 Q26863493-BCAF5D81-449B-4606-88EA-93026CA64F5D Q26996726-2A44ACE1-8667-4A5C-8C5D-88601966CCF1 Q27005894-2343B06E-EE05-46CF-AA15-DC36A937467C Q27687777-269C3902-70C3-4E9D-BE40-EBD457F5DD58 Q28254516-7F1E5AE1-FF54-4063-ADBE-F73D7B0449E8 Q28287394-9FE588B6-D7A6-42C8-9EC6-18FF16F3B540 Q28308042-90B0DE2D-269B-4EF2-A424-BB9E55F6063F Q28727655-7BABAA9F-0B4F-48CA-A10E-F6F27889D143 Q28740575-8E9C91CF-570A-45F9-8710-D26A0FB13B1D Q30837986-9D947125-76F9-4EDB-B4CF-EA9D59ACFE5B Q31021577-3C1647C5-9DD2-4BD8-BCA4-5DC20B5227FB Q31063043-FCB3B492-6B6A-40D5-A494-BD622AE10494 Q33293423-C07B26D9-012B-4A9E-9840-56A4CDA03720 Q33307880-2208F579-D473-4610-AC7B-A0F70288D8B6 Q33563846-7254ABE5-FD37-4653-BDB6-E4228F85AACB Q33567830-E98B722F-F5BC-4E4A-89EA-61CCE8327D2C Q33570337-4E3A8F2B-CB43-4C6D-B502-74A50F0E8874 Q33583525-52B04837-0E4E-4842-B15F-7E66DA120923 Q33619181-B54EC9AD-0F28-4222-BFB3-3ECC9DC6E4B2 Q33663460-517A13EB-63AC-4D2E-B9EF-8805C1705E94 Q33718764-04ED11C4-1B8B-4E68-BCA4-169E631CC438 Q33729548-30E1376F-9D69-4463-B423-52DED9BE253D Q33749157-2F39FEE6-597C-4556-AED9-E677C9F12CA4 Q33754036-D507F463-358E-48C1-A751-52F4CA5C0D93 Q33762943-9D73245F-4110-4F7E-A772-B02F751B961C Q33770418-ED219AEF-2773-4C1D-AD69-C63019EAA4D2 Q33891868-EE4806E6-0C77-4976-8877-546428BD7BB8 Q33977523-7259D399-DAFD-4D8B-8D3E-4EC80ADB3BB2 Q33977536-291280B9-D36B-4E51-98C0-B198D0F1D690 Q34001621-95EC5539-57A4-4749-AEF5-F46CD7C45797

P2860

Denosumab in postmenopausal women with low bone mineral density

http://www.wikidata.org/entity/Q28298728

description

2006 nî lūn-bûn

@nan

2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Denosumab in postmenopausal women with low bone mineral density

@ast

Denosumab in postmenopausal women with low bone mineral density

@en

Denosumab in postmenopausal women with low bone mineral density

@nl

type

label

Denosumab in postmenopausal women with low bone mineral density

@ast

Denosumab in postmenopausal women with low bone mineral density

@en

Denosumab in postmenopausal women with low bone mineral density

@nl

prefLabel

Denosumab in postmenopausal women with low bone mineral density

@ast

Denosumab in postmenopausal women with low bone mineral density

@en

Denosumab in postmenopausal women with low bone mineral density

@nl

P1433

Q28298728-F2F3B981-E564-4DAF-866E-168EA9F418CC

P1476

Q28298728-98ABAE47-6015-4592-988A-BAA84802186B

P2093

Q28298728-1E9A8231-F154-4786-AD77-DCF964035F92

Q28298728-50413AAB-F31F-432D-8992-546E2271892D

Q28298728-5152C0DE-048B-46D4-89F3-A6A48A998D84

Q28298728-520FEB7B-F85C-4022-A3A0-D7A5457B12BA

Q28298728-854501F0-E28B-41F0-B101-DE27C6452D79

Q28298728-88EA3EB9-68F0-485B-8427-BF0CCADA60F3

Q28298728-8E4CB98A-AF3C-4574-B828-20EFFB4143D6

Q28298728-929EDD22-F337-403F-958B-D9C825A5015B

Q28298728-9BFC7D06-4C08-4F3E-A5AF-55200A678E19

Q28298728-9FEF3CE4-2547-45F3-A37E-77E19E4E85F0

P304

Q28298728-FB3914EB-D753-4103-9D03-25FD9438F2CE

P31

Q28298728-DD00A082-4D87-4B87-814F-ABF2EEEEA29C

P3181

Q28298728-F564F799-6891-4050-8CAC-58DF344B1E0A

P356

Q28298728-6F9683DF-06E1-454F-B981-E0514026F4FC

P407

Q28298728-A480BE50-8212-4078-B98F-38DB7C9BB170

P433

Q28298728-03DF8D24-D0EA-4968-918C-5CBA74A51520

P478

Q28298728-73D97EAA-B279-431A-A0FE-34F137AA3CB9

P50

Q28298728-F6CDF02B-6A46-4335-A608-FA5B8EA56C6F

P577

Q28298728-1A8A5DB1-FC0E-4969-991D-1BA7936A22D6

P5875

Q28298728-D5D1FB19-3D18-4A47-B55D-B95CEB3DC135

P698

Q28298728-371DE79F-0C62-4407-AAD8-E22829FC44DF

P3181

P356

P1433

The New England Journal of Medicine

P1476

Denosumab in postmenopausal women with low bone mineral density

@en

P2093

AMG 162 Bone Loss Study Group

http://www.w3.org/2001/XMLSchema#string

Alan J Kivitz

http://www.w3.org/2001/XMLSchema#string

Alfred H Moffett

http://www.w3.org/2001/XMLSchema#string

Charles H Chesnut

http://www.w3.org/2001/XMLSchema#string

Charlie Zhang

http://www.w3.org/2001/XMLSchema#string

Donna L Holloway

http://www.w3.org/2001/XMLSchema#string

Douglas Lain

http://www.w3.org/2001/XMLSchema#string

E Michael Lewiecki

http://www.w3.org/2001/XMLSchema#string

Grattan C Woodson

http://www.w3.org/2001/XMLSchema#string

Mark C Peterson

http://www.w3.org/2001/XMLSchema#string

P304

821-831

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2157013

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA044459

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

354

http://www.w3.org/2001/XMLSchema#string

P50

Michael R McClung

P577

2006-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51374317

http://www.w3.org/2001/XMLSchema#string

P698

16495394

http://www.w3.org/2001/XMLSchema#string